

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:  Cai <i>et al.</i>	Confirmation No.: (to be assigned)  Art Unit: (to be assigned)
Appl. No.: (U.S. National Phase of PCT/US03/15427; U.S. Appl. No. (to be assigned))	Examiner: (to be assigned)  Atty. Docket: 1735.0770001/RWE/CJW
Int'l Filing Date: May 16, 2003	
For: <b>Substituted 4-Aryl-4H-pyrrolo[2,3-<i>h</i>]chromenes and Analogs as Activators of Caspases and Inducers of Apoptosis and the Use Thereof</b>	

**Preliminary Amendment and Submission of Sequence Listing**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450

**Mail Stop PCT**

Sir:

In advance of prosecution, Applicants submit the following amendments and remarks. This Preliminary Amendment is provided in the following format:

- (A) Each section begins on a separate sheet;
- (B) Starting on a separate sheet, amendments to the specification by presenting replacement paragraphs marked up to show changes made;
- (C) Starting on a separate sheet, the Remarks.

It is not believed that extensions of time or fees for net addition of claims are required beyond those that may otherwise be provided for in documents accompanying this paper. However, if additional extensions of time are necessary to prevent abandonment of this application, then such extensions of time are hereby petitioned under 37 C.F.R. § 1.136(a), and any fees required therefor (including fees for net

- 2 -

U.S. National Phase of PCT/US03/15427  
Cai *et al.*

addition of claims) are hereby authorized to be charged to our Deposit Account  
No. 19-0036.